How to Investigate Drug Use in Health Facilities: Selected Drug Use Indicators - EDM Research Series No. 007
(1993; 92 pages) [French] [Spanish]

Table of Contents

	Introduction
		Purpose of drug use indicators
		Objectives of a drug use study
		Background on the development of drug use indicators
		Contents of the manual
		Comments on the manual
	Chapter 1: Overview
		Types of indicators
		Types of drug use studies with indicators
		Steps in organizing and carrying out a drug use study with indicators
	Chapter 2: Core drug use indicators
		Group 1: Prescribing indicators
		Group 2: Patient care indicators
		Group 3: Health facility indicators
	Chapter 3: Study design and sample size
		Select the type of facilities for the study
		Define the types of prescribing encounters to be included
		Choose between retrospective and prospective data
		Sample size
	Chapter 4: Planning and field methods
		Personnel requirements
		Preparations for field work
		Data collection in the field
		Coding of the indicators
	Chapter 5: Analysis and reporting
		Calculating results for each facility
		Displaying the results
		Reporting results at the facility
		Reporting at the administrative level
		Results of earlier drug use studies
	Chapter 6: Follow up questions
		General directions
		Follow-up questions for specific indicators
	Annexes
		Annex 1: Sampling procedures
		Annex 2: Data collection forms
		Annex 3: Examples of earlier studies
		Annex 4: Using the indicators for monitoring
		Annex 5: Complementary drug use indicators
		Annex 6: References

How to Investigate Drug Use in Health Facilities: Selected Drug Use Indicators - EDM Research Series No. 007

World Health Organization
Organisation mondiale de la Santé

WHO/DAP/93.1
Distr: General

Action Programme on Essential Drugs

Contributors

International Network for Rational Use of Drugs

Dr Bimo, Indonesia
Prof A. Chowdhury, Bangladesh
Prof A. Das, Bangladesh
Dr V. Diwan, Sweden
Prof K.K. Kafle, Nepal
Prof B. Mabadeje, Nigeria
Prof A. Massele, Tanzania
Dr R.O. Laing, USA (Network coordinator)
Dr D. Ofori-Adjei, Ghana
Dr D. Ross-Degnan, USA
Prof B. Santoso, Indonesia
Dr G. Tomson, Sweden

World Health Organization

Mrs M. Anker, Epidemiological and Statistical Methodology Unit
Mrs P. Brudon-Jakobowicz, Action Programme on Essential Drugs
Ms D.A. Fresle, Action Programme on Essential Drugs
Dr H.V. Hogerzeil, Action Programme on Essential Drugs

This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, quoted and translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes.